49mon MSN
Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel
Q3 2025 Management View CEO Linda Marbán highlighted the imminent top line readout from the HOPE-3 Phase III clinical study of deramiocel for Duchenne muscular dystrophy, stating this is "just weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback